水黄皮油

Search documents
独家专访 | 二十年磨一剑!他打破PHA成本困局,携万吨级技术回国圆梦!
DT新材料· 2025-06-24 15:32
Core Viewpoint - The article discusses the innovative approach of Yike Biotech in reducing the cost of PHA (polyhydroxyalkanoates) production to compete with petroleum-based materials, emphasizing the use of non-food plant oils as raw materials [3][4][9]. Group 1: Industry Background - The biodegradable materials market, including PLA and PBAT, has faced challenges such as overcapacity and performance limitations, leading to a decline in production rates [6][7]. - PHA is highlighted for its advantages, including marine biodegradability, heat resistance up to 100°C, and excellent barrier properties, with the global market expected to reach $367 million by 2030 [6][8]. Group 2: Company Overview - Yike Biotech was founded in June 2025 by Dr. Wilson Ling, who aims to revolutionize PHA production using non-food oils, specifically Pongamia oil, to significantly lower costs [9][10]. - The company has completed laboratory and pilot-scale validations of its production process and is the first globally to hold a PCT patent for PHA production [37]. Group 3: Cost Reduction Strategy - The raw material cost constitutes over 50% of PHA production costs, making it essential to lower these costs. Traditional sugar-based routes have a conversion rate of only 30%, leading to high costs [27][28]. - By using Pongamia oil, which has a conversion rate of over 80%, Yike Biotech can reduce PHA production costs by 30-50% compared to sugar-based methods [36]. Group 4: Technical and Market Development - Yike Biotech plans to focus on medical products for the Australian market, where demand is high, and the approval process is faster compared to other regions [38]. - The company aims to establish a production line in China that can replace 15,000 to 20,000 tons of petroleum-based plastics annually, with plans for further expansion [39].
独家专访 | 二十年磨一剑!他打破PHA成本困局,携万吨级技术回国圆梦!
合成生物学与绿色生物制造· 2025-06-23 12:35
Core Viewpoint - The article discusses the innovative approach of Ecopha Biotech, founded by Dr. Wilson Ling, to significantly reduce the cost of PHA (polyhydroxyalkanoates) production by utilizing non-food plant oils, specifically Pongamia oil, as a raw material, aiming to compete with traditional petroleum-based plastics [2][9][31]. Group 1: Industry Background - The biodegradable materials market, including PLA and PBAT, has faced challenges such as oversupply and performance limitations, leading to a decline in production rates [6][7]. - PHA stands out due to its advantages like "biomanufacturing," "marine biodegradability," and high thermal resistance (up to 100°C), with the global market expected to reach $367 million by 2030 [6][9]. - The current cost of PHA exceeds 40,000 yuan per ton, making it difficult to compete with petroleum-based plastics priced below 10,000 yuan per ton [7][9]. Group 2: Company Background - Ecopha Biotech was established in June 2025, with Dr. Wilson Ling returning to China after years of research and entrepreneurship abroad, driven by the desire to overcome the cost barriers of PHA production [9][19]. - The company aims to leverage a patented strain of bacteria and non-food oils to achieve a significant reduction in production costs [9][22]. Group 3: Raw Material Cost Reduction - The primary focus for cost reduction is on raw materials, which account for over 50% of PHA production costs. Traditional sugar-based routes have a conversion rate capped at 30%, leading to high costs [22][23]. - Dr. Ling's research determined that using plant oils, particularly Pongamia oil, could achieve a conversion rate of over 80%, significantly lowering production costs [22][31]. - Pongamia oil is non-food, cost-effective (half the price of palm oil), and has a high yield, making it suitable for sustainable production [25][30][31]. Group 4: Technological Advancements - Ecopha Biotech has completed laboratory and pilot-scale validations for using Pongamia oil and has designed a process package for a large-scale production line [32]. - The company plans to focus on medical products initially, targeting the Australian market, where there is a high demand for biodegradable medical supplies [33]. - The first production line in China is expected to replace 15,000 to 20,000 tons of petroleum-based plastics annually once operational [33]. Group 5: Future Outlook - Dr. Ling envisions that the real competition for PHA is not other bioplastics but the vast quantities of petroleum-based plastics that contribute to environmental pollution [34]. - The company aims to collaborate with domestic peers to promote the large-scale industrialization of PHA, potentially alleviating plastic pollution issues as production scales up [34].